Israel -
Hebräisch -
Ministry of Health
לינפארזה 100 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib
Israel -
Hebräisch -
Ministry of Health
לינפארזה 150 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib
Israel -
Hebräisch -
Ministry of Health
לינפארזה 150 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib
Israel -
Hebräisch -
Ministry of Health
לינפארזה 50 מג
astra zeneca (israel) ltd - olaparib - קפסולה קשיחה - olaparib 50 mg - olaparib
Israel -
Hebräisch -
Ministry of Health
נקסיום טבליות 20 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole
Israel -
Hebräisch -
Ministry of Health
נקסיום טבליות 40 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole
Israel -
Hebräisch -
Ministry of Health
נזוקורט אקווה 32 מקגמנה
astra zeneca (israel) ltd - budesonide micronized - ספריי לאף - budesonide micronized 0.64 mg/ml - budesonide - budesonide - seasonal and perennial allergic rhinitis, and vasomotor rhinitis. preventively against nasal polyps after polypectomy. symptomatic treatment in nasal polyposis.
Israel -
Hebräisch -
Ministry of Health
נזוקורט אקווה 64 מקגמנה
astra zeneca (israel) ltd - budesonide micronized - ספריי לאף - budesonide micronized 1.28 mg/ml - budesonide - budesonide - seasonal and perennial allergic rhinitis, and vasomotor rhinitis. preventively against nasal polyps after polypectomy. symptomatic treatment in nasal polyposis.
Israel -
Hebräisch -
Ministry of Health
אונגלייזה 5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.